Total Valuation
SK Biopharmaceuticals Co., Ltd. has a market cap or net worth of ₩5.87T. The enterprise value is $6.45M.
Market Cap₩5.87T
Enterprise Value$6.45M
Share Statistics
SK Biopharmaceuticals Co., Ltd. has 78,313,250 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding78,313,250
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
SK Biopharmaceuticals Co., Ltd.’s return on equity (ROE) is 0.33 and return on invested capital (ROIC) is 22.17%.
Return on Equity (ROE)0.33
Return on Assets (ROA)0.22
Return on Invested Capital (ROIC)22.17%
Return on Capital Employed (ROCE)0.23
Revenue Per Employee2.93B
Profits Per Employee1.11B
Employee Count241
Asset Turnover0.59
Inventory Turnover0.55
Valuation Ratios
The current PE Ratio of SK Biopharmaceuticals Co., Ltd. is 15.1. SK Biopharmaceuticals Co., Ltd.’s PEG ratio is 3.28.
PE Ratio15.1
PS Ratio13.81
PB Ratio12.00
Price to Fair Value12.00
Price to FCF56.19
Price to Operating Cash Flow23.22
PEG Ratio3.28
Income Statement
In the last 12 months, SK Biopharmaceuticals Co., Ltd. had revenue of 706.74B and earned 266.95B in profits. Earnings per share was 3.41K.
Revenue706.74B
Gross Profit651.67B
Operating Income203.94B
Pretax Income150.88B
Net Income266.95B
EBITDA220.89B
Earnings Per Share (EPS)3.41K
Cash Flow
In the last 12 months, operating cash flow was 251.61B and capital expenditures -7.82B, giving a free cash flow of 243.78B billion.
Operating Cash Flow251.61B
Free Cash Flow243.78B
Free Cash Flow per Share3.11K
Dividends & Yields
SK Biopharmaceuticals Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.28
52-Week Price Change-27.91%
50-Day Moving Average82.28K
200-Day Moving Average98.61K
Relative Strength Index (RSI)30.87
Average Volume (3m)127.10K
Important Dates
SK Biopharmaceuticals Co., Ltd. upcoming earnings date is Nov 5, 2026, TBA (Confirmed).
Last Earnings DateAug 5, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
SK Biopharmaceuticals Co., Ltd. as a current ratio of 2.31, with Debt / Equity ratio of 4.78%
Current Ratio2.31
Quick Ratio1.97
Debt to Market Cap<0.01
Net Debt to EBITDA-1.17
Interest Coverage Ratio26.52
Taxes
In the past 12 months, SK Biopharmaceuticals Co., Ltd. has paid -102.37B in taxes.
Income Tax-102.37B
Effective Tax Rate-0.68
Enterprise Valuation
SK Biopharmaceuticals Co., Ltd. EV to EBITDA ratio is 43.00, with an EV/FCF ratio of 54.70.
EV to Sales13.44
EV to EBITDA43.00
EV to Free Cash Flow54.70
EV to Operating Cash Flow52.62
Balance Sheet
SK Biopharmaceuticals Co., Ltd. has ₩381.87B in cash and marketable securities with ₩48.83B in debt, giving a net cash position of ₩333.05B billion.
Cash & Marketable Securities₩381.87B
Total Debt₩48.83B
Net Cash₩333.05B
Net Cash Per Share₩4.25K
Tangible Book Value Per Share₩9.90K
Margins
Gross margin is 91.89%, with operating margin of 28.86%, and net profit margin of 37.77%.
Gross Margin91.89%
Operating Margin28.86%
Pretax Margin21.35%
Net Profit Margin37.77%
EBITDA Margin31.25%
EBIT Margin28.86%
Analyst Forecast
The average price target for SK Biopharmaceuticals Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast38.86%
EPS Growth Forecast56.63%